Nintedanib Esylate contains not less than 98.0 % and not more than 102.0 % of C31H33N5O4‧C2H6O3S, calculated on the anhydrous basis.

共有 1 個藥物證書使用此成份

寧挺達命乙磺酸鹽
Nintedanib Esylate

• 申請商: 東譽興業股份有限公司
• 適應症: 特發性肺纖維化
• 發證日期: 2022-03-09